Elizabeth Buck serves as CHIEF SCIENTIFIC OFFICER at Black Diamond Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Elizabeth Buck has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jan 21, 2026 involved receiving (via award) 250,000 shares valued at $0.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Jan 21, 2026 | BDTX | $0 | Award | 250,000 | $N/A | Discretionary |
Elizabeth Buck currently holds 250,000 shares of Black Diamond Therapeutics, Inc. (BDTX), valued at approximately $0. This represents their equity stake as CHIEF SCIENTIFIC OFFICER.
Based on SEC Form 4 filings, Elizabeth Buck has been a net neutral trader of BDTX stock. They have purchased $0 and sold $0 worth of shares.
Elizabeth Buck's most recent insider trade was on Jan 21, 2026, when they sold 250,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted